Zhang Yunfeng, Wang Duo, Zhu Lizhe, Wang Bin, Ma Xiaoxia, Shi Bohui, Yan Yu, Zhou Can
Department of the Second Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University Department of General Surgery, the Second Affiliated Hospital of Xi'an Medical College Department of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Medicine (Baltimore). 2017 Dec;96(52):e9150. doi: 10.1097/MD.0000000000009150.
The role of extralevator abdominoperineal excision (ELAPE) for distal rectal cancer remains controversial, and the procedure is not widely accepted or practiced.
An electronic search of Medline, EMBASE, Web of Science, and similar databases for articles in English was performed from the inception of the study until October 31, 2017. Two reviewers extracted information and independently assessed the quality of included studies by the methodological index for nonrandomized studies, then data were analyzed with Review Manager 5.3 software and Stata version 12.0 software.
Our meta-analysis included 17 studies with 3479 patients, of whom 1915 (55.0%) underwent ELAPE and 1564 (44.0%) underwent abdominoperineal excision (APE). Compared with patients undergoing APE, patients undergoing ELAPE had a significant reduced risk of no more than 3 years local recurrence (LR) (risk ratio [RR] = 0.27, 95% confidence interval [CI] = 0.08-0.94), 3-year mortality (odds ratio [OR] = 0.45, 95% CI = 0.20-0.97), intraoperative bowel perforation (IBP) involvement (RR = 0.48, 95% CI = 0.31-0.74), and circumferential resection margin (CRM) positivity (RR = 0.66, 95% CI = 0.43-1.00) at the threshold level.
The application of ELAPE is more effective in reducing the chance of 3 years LR, mortality, IBP involvement and CRM positivity than conventional APE, and worthy of being widely applied in surgical treatment of the distal rectal cancer.
经肛提肌外腹会阴联合切除术(ELAPE)在远端直肠癌治疗中的作用仍存在争议,该手术未被广泛接受和应用。
从研究开始至2017年10月31日,对Medline、EMBASE、Web of Science及类似英文数据库进行电子检索。两名研究者提取信息,并依据非随机研究的方法学指标独立评估纳入研究的质量,然后使用Review Manager 5.3软件和Stata 12.0软件进行数据分析。
我们的荟萃分析纳入了17项研究,共3479例患者,其中1915例(55.0%)接受了ELAPE,1564例(44.0%)接受了腹会阴联合切除术(APE)。与接受APE的患者相比,接受ELAPE的患者在不超过3年的局部复发(LR)风险(风险比[RR]=0.27,95%置信区间[CI]=0.08 - 0.94)、3年死亡率(比值比[OR]=0.45,95% CI=0.20 - 0.97)、术中肠穿孔(IBP)累及(RR=0.48,95% CI=0.31 - 0.74)以及环周切缘(CRM)阳性(RR=